Cash flow Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:41:59 10/02/2026 GMT			5-day change	1st Jan Change
15.32 ^USD	+2.37%		+5.28%	-12.18%

01-29	Sector Update: Health Care Stocks Edge Higher Premarket Thursday	MT
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI

85dda48f11a.KnfM2ul97ZivfNf_ckMcCAYURc0I627-uYDwx5sbpGE.fCP766YW3PLEE72ZARt-aXVVIKIwmVjG6uSEo-Ev10xjJoqRmhaB7ukppA

Published financial data: SUMMIT THERAPEUTICS INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Revenues	860K	1.81M	705K	-	-
Other Revenues, Total	-	-	-	-	-
Total Revenues	860K	1.81M	705K	-	-
Gross Profit	860K	1.81M	705K	-	-
Selling General & Admin Expenses, Total	19.23M	23.61M	26.74M	30.26M	60.53M
R&D Expenses	53.27M	85.35M	53.26M	59.47M	151M
Other Operating Expenses	-19.31M	-20.97M	-14.42M	-1M	-313K
Other Operating Expenses, Total	53.19M	88M	65.59M	88.74M	211M
Operating Income	-52.33M	-86.19M	-64.89M	-88.74M	-211M
Interest Expense, Total	-255K	-281K	-4.4M	-16.46M	-8.69M
Interest And Investment Income	4K	-	1.51M	10.4M	13.47M
Net Interest Expenses	-251K	-281K	-2.89M	-6.06M	4.78M
Currency Exchange Gains (Loss)	54K	-2.14M	-4.11M	1.03M	-97K
Other Non Operating Income (Expenses)	480K	-	304K	-252K	-
EBT, Excl. Unusual Items	-52.05M	-88.6M	-71.58M	-94.01M	-206M
Merger & Related Restructuring Charges	-	-	-	-	-
Impairment of Goodwill	-	-	-	-	-
Asset Writedown	-859K	-	-8.47M	-	-
In Process R&D Expenses	-	-	-	-521M	-15.01M
Other Unusual Items	-	-	1.26M	-	-
EBT, Incl. Unusual Items	-52.91M	-88.6M	-78.78M	-615M	-221M
Income Tax Expense	-213K	-	-	-	-
Earnings From Continuing Operations	-52.7M	-88.6M	-78.78M	-615M	-221M
Net Income to Company	-52.7M	-88.6M	-78.78M	-615M	-221M
Net Income - (IS)	-52.7M	-88.6M	-78.78M	-615M	-221M
Net Income to Common Incl Extra Items	-52.7M	-88.6M	-78.78M	-615M	-221M
Net Income to Common Excl. Extra Items	-52.7M	-88.6M	-78.78M	-615M	-221M
Per Share Items
Net EPS - Basic	-0.76	-0.96	-0.41	-0.99	-0.31
Basic EPS - Continuing Operations	-0.76	-0.96	-0.41	-0.99	-0.31
Basic Weighted Average Shares Outstanding	69.52M	92.24M	193M	620M	719M
Net EPS - Diluted	-0.76	-0.96	-0.41	-0.99	-0.31
Diluted EPS - Continuing Operations	-0.76	-0.96	-0.41	-0.99	-0.31
Diluted Weighted Average Shares Outstanding	69.52M	92.24M	193M	620M	719M
Normalized Basic EPS	-0.47	-0.6	-0.23	-0.09	-0.18
Normalized Diluted EPS	-0.47	-0.6	-0.23	-0.09	-0.18
American Depositary Receipts Ratio (ADR)	5	5	5	5	5
Supplemental Items
EBITDA	-50.78M	-84.84M	-63.62M	-88.54M	-211M
EBITA	-51.08M	-85.17M	-63.97M	-88.74M	-211M
EBIT	-52.33M	-86.19M	-64.89M	-88.74M	-211M
EBITDAR	-50.3M	-83.61M	-62.07M	-86.24M	-207M
Effective Tax Rate - (Ratio)	0.4	-	-	-	-
Current Domestic Taxes	-213K	-	-	-	-
Total Current Taxes	-213K	-	-	-	-
Total Deferred Taxes	-	-	-	-	-
Normalized Net Income	-32.53M	-55.38M	-44.74M	-58.76M	-129M
Interest on Long-Term Debt	-	-	-	16.46M	8.7M
Supplemental Operating Expense Items
General and Administrative Expenses	19.23M	23.61M	26.74M	30.26M	60.53M
Research And Development Expense From Footnotes	53.27M	85.35M	52M	580M	166M
Net Rental Expense, Total	478K	1.23M	1.55M	2.3M	3.51M
Imputed Operating Lease Interest Expense	1.44M	1.7M	210K	968K	4.3M
Imputed Operating Lease Depreciation	-958K	-472K	1.34M	1.33M	-795K
Stock-Based Comp., R&D Exp. (Total)	749K	5.91M	4.3M	4.41M	16.01M
Stock-Based Comp., G&A Exp. (Total)	1.02M	6.9M	7.64M	9.7M	34.97M
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	1.77M	12.8M	11.95M	14.11M	50.98M

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Assets
Cash And Equivalents	66.42M	71.79M	349M	71.42M	105M
Short Term Investments	-	-	-	115M	307M
Total Cash And Short Term Investments	66.42M	71.79M	349M	186M	412M
Accounts Receivable, Total	331K	2.04M	349K	-	-
Other Receivables	9.86M	15.7M	5.77M	848K	557K
Total Receivables	10.19M	17.73M	6.12M	848K	557K
Prepaid Expenses	9.55M	7.16M	1.5M	2.44M	10.52M
Restricted Cash	-	-	300M	-	325K
Other Current Assets, Total	1.52M	627K	486K	181K	-
Total Current Assets	87.67M	97.31M	657M	190M	424M
Gross Property Plant And Equipment	2.41M	6.86M	6.38M	7.1M	8.52M
Accumulated Depreciation	-1.13M	-3.38M	-1.3M	-1.04M	-1.12M
Net Property Plant And Equipment	1.28M	3.48M	5.08M	6.06M	7.4M
Goodwill	2.03M	2.01M	1.8M	1.89M	1.86M
Other Intangibles, Total	11.52M	10.4M	-	-	-
Other Long-Term Assets, Total	-	170K	577K	5.28M	2.55M
Total Assets	102M	113M	664M	203M	436M
Liabilities
Accounts Payable, Total	6.14M	4.37M	355K	2.67M	4.64M
Accrued Expenses, Total	4.26M	11.32M	16.3M	14.21M	31.53M
Current Portion of Long-Term Debt	-	-	19.77M	-	-
Current Portion of Leases	390K	1.09M	1.69M	2.81M	3.76M
Current Income Taxes Payable	-	-	-	-	-
Unearned Revenue Current, Total	8.37M	7.94M	-	-	-
Other Current Liabilities	729K	897K	662K	717K	1.8M
Total Current Liabilities	19.89M	25.62M	38.78M	20.4M	41.73M
Long-Term Debt	-	-	495M	100M	-
Long-Term Leases	75K	1.69M	2.76M	3.29M	3.45M
Unearned Revenue Non Current	569K	-	-	-	-
Deferred Tax Liability Non Current	-	-	-	-	-
Other Non Current Liabilities	2.51M	2.78M	1.43M	1.56M	1.63M
Total Liabilities	23.04M	30.09M	538M	125M	46.81M
Common Stock, Total	826K	980K	2.11M	7.02M	7.38M
Additional Paid In Capital	293M	384M	505M	1.07B	1.6B
Retained Earnings	-211M	-300M	-378M	-993M	-1.21B
Comprehensive Income and Other	-3.79M	-2.2M	-1.89M	-2.45M	-2.28M
Total Common Equity	79.45M	83.28M	127M	77.69M	389M
Total Equity	79.45M	83.28M	127M	77.69M	389M
Total Liabilities And Equity	102M	113M	664M	203M	436M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	82.92M	98.12M	698M	702M	738M
ECS Total Common Shares Outstanding	82.58M	98.04M	211M	702M	738M
Book Value / Share	0.96	0.85	0.6	0.11	0.53
Tangible Book Value	65.91M	70.88M	125M	75.8M	387M
Tangible Book Value Per Share	0.8	0.72	0.59	0.11	0.52
Total Debt	465K	2.78M	519M	106M	7.22M
Net Debt	-65.95M	-69.01M	170M	-80.14M	-405M
Debt Equivalent Oper. Leases	3.82M	9.82M	12.42M	18.38M	28.07M
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	1.56M	3.71M	1.39M	918K	1.05M
Full Time Employees	79	105	76	105	159
Part Time Employees	2	5	1	-	-

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Net Income	-52.7M	-88.6M	-78.78M	-615M	-221M
Depreciation & Amortization - CF	753K	1.44M	1.6M	2.05M	89K
Amortization of Goodwill and Intangible Assets - (CF)	1.25M	1.02M	914K	-	-
Depreciation & Amortization, Total	2M	2.46M	2.51M	2.05M	89K
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	-
(Gain) Loss From Sale Of Asset	2K	-	-	-109K	-
(Gain) Loss on Sale of Investments - (CF)	-	-	-	-1.92M	-2.58M
Asset Writedown & Restructuring Costs	859K	-	8.47M	521M	15.01M
Stock-Based Compensation (CF)	1.77M	12.8M	11.95M	14.11M	50.98M
Other Operating Activities, Total	-663K	823K	5.65M	5.02M	229K
Change In Accounts Receivable	212K	-1.14M	975K	359K	-
Change In Accounts Payable	1.64M	-1.71M	-4.13M	2.26M	2.02M
Change in Unearned Revenues	5.37M	-813K	-7.28M	-	-
Change in Other Net Operating Assets	-6.61M	3.6M	19.05M	-4.99M	13.46M
Cash from Operations	-48.11M	-72.59M	-41.58M	-76.76M	-142M
Capital Expenditure	-421K	-306K	-624K	-128K	-139K
Sale of Property, Plant, and Equipment	-	-	-	226K	-
Cash Acquisitions	-	-	-	-	-
Sale (Purchase) of Intangible assets	-	-	-	-475M	-15.01M
Investment in Marketable and Equity Securities, Total	-	-	-	-113M	-190M
Other Investing Activities, Total	-	-	-	-	-
Cash from Investing	-421K	-306K	-624K	-588M	-205M
Short Term Debt Issued, Total	-	110M	545M	-	-
Long-Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	110M	545M	-	-
Short Term Debt Repaid, Total	-	-110M	-25M	-	-
Long-Term Debt Repaid, Total	-	-	-	-24.69M	-100M
Total Debt Repaid	-	-110M	-25M	-24.69M	-100M
Issuance of Common Stock	50.6M	78.09M	100M	112M	481M
Other Financing Activities, Total	-48K	-172K	-155K	-619K	-
Cash from Financing	50.55M	77.92M	620M	86.51M	381M
Foreign Exchange Rate Adjustments	556K	351K	-1.22M	839K	-18K
Net Change in Cash	2.58M	5.37M	577M	-577M	33.76M
Supplemental Items
Cash Interest Paid	-	85K	434K	10.65M	8.81M
Cash Income Tax Paid (Refund)	-70K	7K	-	52K	-
Levered Free Cash Flow	-28.79M	-38.32M	-319M	-220M	-88.94M
Unlevered Free Cash Flow	-28.63M	-38.15M	-317M	-210M	-83.51M
Change In Net Working Capital	-733K	-768K	290M	-305M	-12.44M
Net Debt Issued / Repaid	-	0	520M	-24.69M	-100M

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Profitability
Return on Assets	-32.92	-49.91	-10.43	-12.79	-41.31
Return on Total Capital	-40.97	-64.91	-11.09	-13.38	-45.49
Return On Equity %	-66.57	-108.89	-75.05	-601.85	-94.9
Return on Common Equity	-66.57	-108.89	-75.05	-601.85	-94.9
Margin Analysis
Gross Profit Margin %	100	100	100	-	-
SG&A Margin	2.24K	1.31K	3.79K	-	-
EBITDA Margin %	-5.9K	-4.69K	-9.02K	-	-
EBITA Margin %	-5.94K	-4.71K	-9.07K	-	-
EBIT Margin %	-6.09K	-4.76K	-9.2K	-	-
Income From Continuing Operations Margin %	-6.13K	-4.9K	-11.17K	-	-
Net Income Margin %	-6.13K	-4.9K	-11.17K	-	-
Net Avail. For Common Margin %	-6.13K	-4.9K	-11.17K	-	-
Normalized Net Income Margin	-3.78K	-3.06K	-6.35K	-	-
Levered Free Cash Flow Margin	-3.35K	-2.12K	-45.29K	-	-
Unlevered Free Cash Flow Margin	-3.33K	-2.11K	-44.9K	-	-
Asset Turnover
Asset Turnover	0.01	0.02	0	-	-
Fixed Assets Turnover	0.61	0.76	0.16	-	-
Receivables Turnover (Average Receivables)	1.97	1.53	0.78	-	-
Short Term Liquidity
Current Ratio	4.41	3.8	16.93	9.3	10.15
Quick Ratio	3.85	3.49	9.15	9.17	9.89
Operating Cash Flow to Current Liabilities	-2.42	-2.83	-1.07	-3.76	-3.41
Days Sales Outstanding (Average Receivables)	185.55	239	469.32	-	-
Long Term Solvency
Total Debt/Equity	0.59	3.34	409.59	136.56	1.86
Total Debt / Total Capital	0.58	3.23	80.38	57.73	1.82
LT Debt/Equity	0.09	2.03	392.65	132.95	0.89
Long-Term Debt / Total Capital	0.09	1.96	77.05	56.2	0.87
Total Liabilities / Total Assets	22.48	26.54	80.93	61.72	10.75
EBIT / Interest Expense	-205.23	-306.71	-14.74	-5.39	-24.29
EBITDA / Interest Expense	-197.27	-297.55	-14.1	-5.24	-23.88
(EBITDA - Capex) / Interest Expense	-198.92	-298.64	-14.25	-5.25	-23.89
Total Debt / EBITDA	-0.01	-0.03	-8.36	-1.23	-0.03
Net Debt / EBITDA	1.31	0.83	-2.74	0.93	1.95
Total Debt / (EBITDA - Capex)	-0.01	-0.03	-8.27	-1.23	-0.03
Net Debt / (EBITDA - Capex)	1.3	0.82	-2.71	0.93	1.95
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	6.1	110.35	-61.03	-	-
Gross Profit, 1 Yr. Growth %	6.1	110.35	-61.03	-	-
EBITDA, 1 Yr. Growth %	77.79	67.07	-25.01	39.16	138.21
EBITA, 1 Yr. Growth %	76.69	66.72	-24.89	38.71	137.78
EBIT, 1 Yr. Growth %	74.62	64.68	-24.71	36.76	137.78
Earnings From Cont. Operations, 1 Yr. Growth %	65.84	68.13	-11.08	680.54	-64.01
Net Income, 1 Yr. Growth %	65.84	68.13	-11.08	680.54	-64.01
Normalized Net Income, 1 Yr. Growth %	64.01	70.22	-19.21	31.34	119.45
Diluted EPS Before Extra, 1 Yr. Growth %	-21.72	26.39	-57.32	142.05	-68.76
Accounts Receivable, 1 Yr. Growth %	-38.82	515.71	-76.16	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	-16.89	172.4	45.84	19.33	22.02
Total Assets, 1 Yr. Growth %	6.49	10.61	485.82	-69.44	114.62
Tangible Book Value, 1 Yr. Growth %	3.33	7.54	76.16	-39.29	410.41
Common Equity, 1 Yr. Growth %	0.75	4.82	52.07	-38.66	400.37
Cash From Operations, 1 Yr. Growth %	112.47	50.87	-42.71	84.6	85.13
Capital Expenditures, 1 Yr. Growth %	88.25	-27.32	103.92	-79.49	8.59
Levered Free Cash Flow, 1 Yr. Growth %	-	33.12	733.65	-31.15	-59.88
Unlevered Free Cash Flow, 1 Yr. Growth %	-	33.25	729.75	-33.8	-60.5
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	49.39	-9.46	-	-
Gross Profit, 2 Yr. CAGR %	-	49.39	-9.46	-	-
EBITDA, 2 Yr. CAGR %	-	72.35	11.93	2.16	83.91
EBITA, 2 Yr. CAGR %	-	71.63	11.91	2.07	83.43
EBIT, 2 Yr. CAGR %	-	69.58	11.35	1.47	82.11
Earnings From Cont. Operations, 2 Yr. CAGR %	-	66.99	22.27	163.45	67.61
Net Income, 2 Yr. CAGR %	-	66.99	22.27	163.45	67.61
Normalized Net Income, 2 Yr. CAGR %	-	67.09	17.27	3.01	71.29
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-0.53	-26.55	1.64	-13.05
Accounts Receivable, 2 Yr. CAGR %	-	94.09	2.68	-	-
Net Property, Plant and Equip., 2 Yr. CAGR %	-	50.46	99.31	31.92	20.67
Total Assets, 2 Yr. CAGR %	-	8.53	154.55	33.79	-19.02
Tangible Book Value, 2 Yr. CAGR %	-	5.41	37.64	3.41	76.03
Common Equity, 2 Yr. CAGR %	-	2.76	26.26	-3.42	75.2
Cash From Operations, 2 Yr. CAGR %	-	79.04	-7.03	2.83	84.86
Capital Expenditures, 2 Yr. CAGR %	-	16.97	21.74	-35.32	-52.8
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	233.02	139.58	-47.26
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	232.51	134.37	-48.67
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	-	-4.54	-	-
Gross Profit, 3 Yr. CAGR %	-	-	-4.54	-	-
EBITDA, 3 Yr. CAGR %	-	-	30.6	20.36	35.47
EBITA, 3 Yr. CAGR %	-	-	30.31	20.21	35.31
EBIT, 3 Yr. CAGR %	-	-	29.37	19.24	34.77
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	35.35	126.82	35.68
Net Income, 3 Yr. CAGR %	-	-	35.35	126.82	35.68
Normalized Net Income, 3 Yr. CAGR %	-	-	31.14	21.78	32.54
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-24.98	9.3	-31.41
Accounts Receivable, 3 Yr. CAGR %	-	-	-13.59	-	-
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	48.9	67.99	28.53
Total Assets, 3 Yr. CAGR %	-	-	90.38	25.57	56.62
Tangible Book Value, 3 Yr. CAGR %	-	-	25.09	4.77	76.07
Common Equity, 3 Yr. CAGR %	-	-	17.11	-0.74	67.12
Cash From Operations, 3 Yr. CAGR %	-	-	22.46	16.85	25.1
Capital Expenditures, 3 Yr. CAGR %	-	-	40.78	-32.76	-23.13
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	-	96.92	32.43
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	-	94.16	29.85
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-	-	-	-
Gross Profit, 5 Yr. CAGR %	-	-	-	-	-
EBITDA, 5 Yr. CAGR %	-	-	-	-	49.16
EBITA, 5 Yr. CAGR %	-	-	-	-	48.81
EBIT, 5 Yr. CAGR %	-	-	-	-	47.75
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	-	47.43
Net Income, 5 Yr. CAGR %	-	-	-	-	47.43
Normalized Net Income, 5 Yr. CAGR %	-	-	-	-	45.41
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-	-20.41
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	-	-	36.89
Total Assets, 5 Yr. CAGR %	-	-	-	-	35.25
Tangible Book Value, 5 Yr. CAGR %	-	-	-	-	43.41
Common Equity, 5 Yr. CAGR %	-	-	-	-	37.58
Cash From Operations, 5 Yr. CAGR %	-	-	-	-	44.39
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-	-9.07
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	-
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	-